Ellie Corigliano

Company: GlaxoSmithKline

Job title: Head of CDx Cell & Gene Therapies Oncology

Seminars:

Transforming the Recruitment Process & Returning to Work in the Post-COVID19 Era – Further Accelerating Our Industry’s Journey to Becoming Truly Equal, Diverse & Inclusive 12:00 pm

How are precision medicine leaders ensuring that the next generation of decision makers represent the diverse pool of the community? How does having a diverse executive team help accelerate the industry’s journey to becoming truly diverse? How are companies approaching the return-to-work procedure? What challenges are arising?Read more

day: ED&I CDx Engage Workshop

Panel Discussion: How to Know When a CDx & a Predictive Biomarker is Needed for a Drug 4:00 pm

Discussing criteria determining which drugs to progress for CDx selection to inform clinical strategy and investment plan Changing requirements to implement a diagnostic in the early phase clinical trial Vs what’s needed for later approval Engaging different arms of the business, to build trust for CDx development Pre-empting bottlenecks in Dx development to de-risk investmentRead more

day: Day One

Use of NY-ESO-1 TCR T-Cell Therapy in Patients with Mixed Round Cell Liposarcoma Whose Tumors are NYESO-1 Positive 2:00 pm

Letetresgene autoleucel (lete-cel; GSK3377794) is a T-cell receptor (TCR) T-cell therapy specific to the NY-ESO-1 peptide-displaying antigen, a highly immunogenic cancer/testis antigen expressed in myxoid round cell liposarcoma that promotes an anticancer immune response Early development of NY-ESO-1 immunohistochemistry detection suggests a companion diagnostic path forward for clinical developmentRead more

day: Track B - Day 1 PM